The VSV-G envelope protein fused with anti-CD30 scFV pseudotyping targets CD30+ lymphocytes [301], while the VSV-G fused with anti-EGFR scFV pseudotyping targets EGFR+ tumor cells [302]; furthermore, with poloxamer-based adjuvants, higher infectivity to the target cells than typical VSV-G pseudotyped LV was observed, offering potential in terms of cancer and immunotherapy. This evidence concerns the gene TNFRSF8 and cancer.